康缘药业(600557) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was CNY 1,352,493,841.95, representing a 25.39% increase year-over-year[19]. - The net profit attributable to shareholders for Q1 2023 was CNY 141,438,358.86, reflecting a 28.60% increase compared to the same period last year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 139,362,939.64, up 30.70% year-over-year[19]. - The basic earnings per share for Q1 2023 was CNY 0.25, an increase of 31.58% compared to the previous year[19]. - The diluted earnings per share for Q1 2023 was CNY 0.24, reflecting a 26.32% increase year-over-year[19]. - Net profit for Q1 2023 was ¥145,272,114.36, compared to ¥110,378,236.08 in Q1 2022, representing a 31.6% growth[45]. - Total comprehensive income amounts to 145,272,114.36, an increase from 110,378,236.08[49]. - Total comprehensive income attributable to the parent company is 141,438,358.86, up from 109,985,159.38[49]. Cash Flow and Assets - The net cash flow from operating activities was CNY -60,672,699.77, a decrease of 176.67% compared to the same period last year[19]. - Cash flow from operating activities in Q1 2023 showed a net outflow of ¥60,672,699.77, compared to a net inflow of ¥79,139,904.88 in Q1 2022[46]. - The total assets at the end of Q1 2023 were CNY 6,718,199,483.33, a decrease of 1.14% from the end of the previous year[19]. - The total assets as of Q1 2023 were ¥6,718,199,483.33, down from ¥6,795,804,201.36 in the previous year[43]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,177, with Jiangsu Kangyuan Group Co., Ltd. holding 30.14% of shares[25]. - The equity attributable to shareholders at the end of Q1 2023 was CNY 4,895,632,854.76, representing a 2.98% increase from the end of the previous year[19]. - The total equity attributable to shareholders of the parent company is 4,895,632,854.76 RMB, an increase from 4,754,194,495.90 RMB[29]. Liabilities - The total liabilities amount to 1,641,294,557.35 RMB, down from 1,861,811,589.74 RMB in the previous period[29]. - The company’s total liabilities decreased from ¥1,781,105,699.00 in the previous year to ¥1,561,334,431.09 in Q1 2023, a decline of approximately 12.3%[43]. - The total non-current liabilities amount to 79,960,126.26 RMB, slightly down from 80,705,890.74 RMB[29]. Research and Development - Research and development expenses in Q1 2023 amounted to ¥188,577,937.82, an increase from ¥144,196,379.61 in Q1 2022, indicating a 30.8% rise[44]. Other Financial Information - The company recorded a government subsidy of 4,035,535.94 RMB, which is closely related to its normal business operations[21]. - The company experienced a loss of 253,015.40 RMB from the disposal of non-current assets[21]. - The company’s investment income for Q1 2023 was ¥447,980.55, down from ¥1,127,010.39 in Q1 2022, reflecting a decrease of 60.3%[44]. - The net profit attributable to the parent company's shareholders is 141,438,358.86, up from 109,985,159.38[49]. - The net profit attributable to minority shareholders is 3,833,755.50, compared to 393,076.70 previously[49]. - The company did not apply new accounting standards or interpretations starting in 2023[51].